Table 1. The details of the 9 patients.

No.	Age/sex	Histology	Involved level	Enneking stage	ASIA			ECOG			VAS		Follow-up (months)	Final status	Total operative time (min)	Estimated blood loss (mL)	Complications	Hospital duration (day)	Adjuvant therapy	Segment height (mm)
					Preoperative	Final follow-up		Preoperative	Final follow-up		Preoperative	Final follow-up								Immediately postoperative	At final follow-up
1	12/M	Ewing sarcoma	C2	IIB	D	Died		3	5		8	Died	15	DOD	541	1,400	None	33	RT and CHT	53.1	53.2
2	24/F	GCT	C2	S3	D	E		3	0		5	0	42	NED	395	300	None	25	RT	45.3	45.0
3	17/F	GCT	C2	S3	E	E		3	0		10	1	41	NED	451	3,300	None	20	RT	50.5	50.1
4	47/F	Paraganglioma	C2	IIB	E	E		4	1		6	2	39	NED	356	1,600	None	14	RT and CHT	54.5	54.4
5	44/M	Hemangioendothelioma	C2–C3	IIB	E	E		3	1		9	2	34	NED	559	6,400	None	37	RT	52.9	52.6
6	18/F	GCT	C2	S3	E	E		3	0		6	0	32	NED	366	750	None	49	RT	43.1	43.0
7	59/F	Chordoma	C2	IB	E	E		3	1		7	2	27	AWD	456	1,100	None	20	RT	51.3	51.0
8	16/F	GCT	C2	S3	E	E		4	0		9	0	15	NED	432	500	None	30	RT	48.9	48.4
9	46/F	Chordoma	C2–C3	IB	E	E		2	0		4	0	12	NED	485	1,700	CSF leakage, poor wound healing	30	RT	66.8	66.0

GCT, giant cell tumor; DOD, died of the disease; NED, no evidence of disease; AWD, alive with disease; RT, radiation therapy; CHT, chemotherapy; CSF, cerebrospinal fluid.